Pamela Drullinsky, MD
Medical Oncology · Rockville Centre, NYNPI 1902886369
Payments from drug & device makers
Across 54 payments — averaging $36,484 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.8M
- Genentech, Inc.$181K
- Karyopharm Therapeutics Inc.$12
- Gilead$12
Across 7 payments — averaging $2478.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15K
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Education$24100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $1,789,271 |
| Genentech, Inc. | 42 | $180,843 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$1,970,138 in reported general payments places this provider in the 75th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 76 | $1,068,766 |
| IbrancePalbociclib | 56 | $845,763 |
| XareltoRivaroxaban | 19 | $12,320 |
| Exemestane | 44 | $5,945 |
| Anastrozole | 197 | $3,600 |
| Letrozole | 93 | $1,493 |
| Tamoxifen Citrate | 45 | $1,261 |
| Ibandronate Sodium | 22 | $499 |
| Hydroxyzine Hcl | 11 | $269 |
| Ondansetron Hcl | 31 | $262 |
| Gabapentin | 13 | $123 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rockville Centre
- Anthony MatoIthaca$40.3M
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.